PT1850873T - Anticorpos contra tgfbeta - Google Patents

Anticorpos contra tgfbeta

Info

Publication number
PT1850873T
PT1850873T PT06734583T PT06734583T PT1850873T PT 1850873 T PT1850873 T PT 1850873T PT 06734583 T PT06734583 T PT 06734583T PT 06734583 T PT06734583 T PT 06734583T PT 1850873 T PT1850873 T PT 1850873T
Authority
PT
Portugal
Prior art keywords
tgfbeta
antibodies
Prior art date
Application number
PT06734583T
Other languages
English (en)
Inventor
G Holgate Robert
R Ledbetter Steven
P Hart Celia
U Jermutus Lutz
L Buchanan Catriona
R Duncan Alexander
K Finch Donna
Original Assignee
Genzyme Corp
Optein Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Optein Inc filed Critical Genzyme Corp
Publication of PT1850873T publication Critical patent/PT1850873T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT06734583T 2005-02-08 2006-02-08 Anticorpos contra tgfbeta PT1850873T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65134305P 2005-02-08 2005-02-08

Publications (1)

Publication Number Publication Date
PT1850873T true PT1850873T (pt) 2019-02-19

Family

ID=36793677

Family Applications (2)

Application Number Title Priority Date Filing Date
PT182083824T PT3520815T (pt) 2005-02-08 2006-02-08 Anticorpos contra tgfbeta
PT06734583T PT1850873T (pt) 2005-02-08 2006-02-08 Anticorpos contra tgfbeta

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT182083824T PT3520815T (pt) 2005-02-08 2006-02-08 Anticorpos contra tgfbeta

Country Status (20)

Country Link
US (11) US7723486B2 (pt)
EP (2) EP1850873B1 (pt)
JP (5) JP5174466B2 (pt)
CN (3) CN104151427B (pt)
AU (1) AU2006213875B2 (pt)
BR (1) BRPI0607639B1 (pt)
CA (2) CA2930677A1 (pt)
CY (1) CY1121424T1 (pt)
DK (1) DK1850873T3 (pt)
ES (2) ES2711213T3 (pt)
HK (2) HK1201859A1 (pt)
HU (1) HUE042689T2 (pt)
IL (3) IL184995A (pt)
LT (1) LT1850873T (pt)
MX (1) MX2007009545A (pt)
PL (2) PL3520815T3 (pt)
PT (2) PT3520815T (pt)
SI (1) SI1850873T1 (pt)
TR (1) TR201901929T4 (pt)
WO (1) WO2006086469A2 (pt)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2005097832A2 (en) * 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
CN104151427B (zh) 2005-02-08 2017-09-08 根茨美公司 针对TGFβ的抗体
EP2918288B1 (en) 2006-10-03 2017-08-16 Genzyme Corporation Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
BRPI0807710B1 (pt) * 2007-02-23 2021-12-14 Merck Sharp & Dohme Corp Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
SG178804A1 (en) * 2007-02-23 2012-03-29 Schering Corp Engineered anti-il-23p19 antibodies
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
CA2939492C (en) 2009-05-13 2019-03-19 Genzyme Corporation Anti-human cd52 immunoglobulins
CA3101298A1 (en) 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
SI3117709T1 (sl) 2010-03-12 2018-12-31 Genzyme Corporation Kombinirana terapija za zdravljenje raka dojke
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
ES2715177T3 (es) * 2010-09-01 2019-06-03 Genzyme Corp Tratamiento de infarto de miocardio usando antagonistas de tgf-beta
AU2011329638C1 (en) 2010-11-18 2017-04-27 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
EP2640744A4 (en) 2010-11-19 2014-05-28 Eisai R&D Man Co Ltd NEUTRALIZATION OF ANTIBODIES TO CCL20
BR112013030958B1 (pt) 2011-06-03 2022-02-08 Xoma Technology Ltd Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo
EP2737083A1 (en) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Methods for diagnosing and treating myhre syndrome
WO2013062544A1 (en) 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
WO2013078286A1 (en) 2011-11-22 2013-05-30 Cornell University Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling
BR112014022200A2 (pt) 2012-03-08 2019-09-24 Selig Sealing Products Inc membro de vedação de recipiente com compodnente de segurança protegido e aba de remoção
ES2694203T3 (es) 2012-03-08 2018-12-19 Ludwig Institute For Cancer Research Limited Anticuerpos específicos del Tgf-1 y métodos y usos de los mismos
KR102258457B1 (ko) * 2013-03-11 2021-05-31 젠자임 코포레이션 조작된 항-tgf-베타 항체 및 항원-결합 단편
SI2970890T1 (sl) 2013-03-14 2020-10-30 The Brigham And Women's Hospital, Inc. Sestavki in postopki za razmnoževanje in kultiviranje epitelijskih matičnih celic
SI3312195T1 (sl) * 2013-03-20 2020-02-28 Genzyme Corporation Postopki zdravljenja osteogeneze imperfecta
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
US10357507B2 (en) * 2014-05-16 2019-07-23 Sheau-Long Lee Use of ginsenoside M1 for inhibiting renal fibrosis
EP3189134A1 (en) 2014-09-03 2017-07-12 The Brigham and Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
US11253546B2 (en) 2014-12-15 2022-02-22 The Regents Of The University Of California Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
AU2016206682B2 (en) 2015-01-14 2021-11-11 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-LAP monoclonal antibodies
US10167334B2 (en) 2015-04-03 2019-01-01 Xoma Technology Ltd. Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
EP3307772B1 (en) 2015-06-12 2020-09-09 Ludwig Institute For Cancer Research Limited Tgf-beta 3 specific antibodies and methods and uses thereof
TW201718010A (zh) * 2015-06-19 2017-06-01 健臻公司 治療原發性局部節段性腎小球硬化症之方法
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CA2994413A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma, Inc. Methods for treating myeloproliferative disorders
HUE061424T2 (hu) * 2015-10-30 2023-06-28 Univ California Növekedési faktor bétára reagáló polipeptidek transzformálása és azok felhasználási módszerei
MX2018007423A (es) 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
US11021687B2 (en) 2016-01-08 2021-06-01 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
JP2019506390A (ja) * 2016-01-21 2019-03-07 ザ スクリプス リサーチ インスティテュート 合成オピオイドワクチン
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
CA3055555A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgf.beta.1-binding immunoglobulins and use thereof
MX2018014047A (es) 2016-05-17 2019-06-20 Genentech Inc Firmas de genes estromales para el diagnóstico y uso en inmunoterapia.
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
AU2017310344A1 (en) * 2016-08-11 2019-03-07 Precithera, Inc. TGF-β antagonist conjugates
EP3506943A4 (en) 2016-09-02 2020-04-22 The Regents of The University of California METHODS AND COMPOSITIONS INVOLVING SINGLE CHAIN VARIABLE FRAGMENTS (SCFV) BINDING TO THE INTERLEUKIN-6 ALPHA RECEPTOR
TW201811827A (zh) * 2016-09-05 2018-04-01 日商中外製藥股份有限公司 抗ＴＧＦ－β１抗體及使用方法
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
SG10201910821XA (en) 2016-12-30 2020-01-30 Frequency Therapeutics Inc 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
US20180207267A1 (en) 2017-01-06 2018-07-26 Scholar Rock, Inc. Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
WO2018134681A1 (en) 2017-01-20 2018-07-26 Sanofi Anti-tgf-beta antibodies and their use
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
KR102635723B1 (ko) 2017-05-04 2024-02-08 악셀레론 파마 인코포레이티드 Tgf-베타 수용체 유형 ii 융합 단백질 및 이의 용도
PE20200717A1 (es) 2017-06-22 2020-07-21 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
KR20200075860A (ko) 2017-11-06 2020-06-26 제넨테크, 인크. 암의 진단 및 치료 방법
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
BR112020010579A2 (pt) 2017-11-30 2020-11-10 Novartis Ag receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo
MX2020009394A (es) 2018-03-09 2021-01-15 Agenus Inc Anticuerpos anti-cd73 y métodos de uso de los mismos.
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
JP2021530461A (ja) * 2018-07-10 2021-11-11 サノフイSanofi Ｃｄ３８およびｔｇｆ−ベータを標的とする、がんに対する組合せ療法
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
TW202005981A (zh) 2018-07-11 2020-02-01 美商供石公司 高親和性、異構體選擇性之TGFβ1抑制劑及其用途
EP3820896A1 (en) 2018-07-11 2021-05-19 Scholar Rock, Inc. TGFbeta1 INHIBITORS AND USE THEREOF
MA52165A (fr) 2018-07-11 2021-06-02 Scholar Rock Inc Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
AU2019328313A1 (en) 2018-08-30 2021-02-25 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
AU2019375036A1 (en) 2018-11-05 2021-06-03 Centre Hospitalier Universitaire Vaudois Humanized and variant TGF-beta1 specific antibodies and methods and uses thereof
US20210388074A1 (en) 2018-11-05 2021-12-16 Ludwig Institute For Cancer Research Ltd. Humanized and variant tgf-beta3 specific antibodies and methods and uses thereof
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
PE20220279A1 (es) 2019-01-30 2022-02-25 Scholar Rock Inc Inhibidores especificos del complejo de ltbp de tgf beta y usos de los mismos
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
CA3152371A1 (en) 2019-08-01 2021-02-04 Vaccinex, Inc. Combined inhibition of semaphorin-4d and tgf.beta. and compositions therefor
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
AU2020372413A1 (en) 2019-10-23 2022-06-09 Cue Biopharma, Inc. TGF-beta polypeptides
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
AU2021205433A1 (en) 2020-01-11 2022-08-18 Scholar Rock, Inc. Tgfß inhibitors and use thereof
CN117551194A (zh) 2020-03-19 2024-02-13 基因泰克公司 同种型选择性抗TGF-β抗体及使用方法
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
KR20230104651A (ko) 2020-11-06 2023-07-10 노파르티스 아게 Cd19 결합 분자 및 이의 용도
US20220162288A1 (en) 2020-11-25 2022-05-26 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
JP2024505049A (ja) 2021-01-29 2024-02-02 ノバルティス アーゲー 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
IL305181A (en) 2021-02-15 2023-10-01 Takeda Pharmaceuticals Co Cell therapy compositions and methods for modulating TGF-B signaling
CA3207134A1 (en) 2021-02-19 2022-08-25 Jeffrey A. Ledbetter Dnase fusion polypeptides and related compositions and methods
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
KR20240046887A (ko) 2021-08-11 2024-04-11 에이치씨더블유 바이올로직스, 인크. 다중-사슬 키메라 폴리펩타이드 및 간 질환의 치료에 있어서 이의 용도
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023201311A1 (en) 2022-04-13 2023-10-19 HCW Biologics, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
WO2023201310A1 (en) 2022-04-13 2023-10-19 HCW Biologics, Inc. Multi-chain chimeric polypeptide for use in the treatment of circardian clock gene disorder
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2056642B (en) 1979-08-08 1983-05-11 Dawson Int Radio frequency drying of textile material
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2101269A1 (en) 1990-12-10 1992-06-11 Carl A. Scotto Fork-lift attachment
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
US5543143A (en) * 1992-03-06 1996-08-06 Corixa Corporation Method for activating macrophages/monocytes
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
KR100487456B1 (ko) 1996-03-10 2005-11-25 메이지 데어리즈 코포레이션 알레르기질환에대한펩티드면역치료제
EP2154535A1 (en) 1998-12-10 2010-02-17 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
TR200102715T2 (tr) 1999-03-25 2002-09-23 Knoll Gmbh Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
IL151499A0 (en) 2000-03-03 2003-04-10 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
YU45103A (sh) * 2000-12-06 2006-08-17 Applied Research Systems Ars Holding N.V. Upotreba sarp/1 za lečenje i prevenciju skleroderme
WO2004018430A1 (ja) * 2002-08-23 2004-03-04 Kirin Beer Kabushiki Kaisha ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
EP1620128A1 (en) 2003-04-30 2006-02-01 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
JP2005112812A (ja) * 2003-10-09 2005-04-28 Zeria Pharmaceut Co Ltd リン酸化部位特異的抗体及びそれを用いたスクリーニング方法
WO2005056772A1 (en) 2003-12-09 2005-06-23 Novozymes Inc. Methods for eliminating or reducing the expression of genes in filamentous fungal strains
WO2005097832A2 (en) * 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
KR100749566B1 (ko) * 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
CN104151427B (zh) * 2005-02-08 2017-09-08 根茨美公司 针对TGFβ的抗体
ITMI20110376A1 (it) 2011-03-10 2012-09-11 Wilic Sarl Aerogeneratore raffreddato a fluido
DE102011078333A1 (de) 2011-06-29 2013-01-03 Siemens Aktiengesellschaft Überspannungsableiter

Also Published As

Publication number Publication date
CN104151427A (zh) 2014-11-19
CN104151427B (zh) 2017-09-08
SI1850873T1 (sl) 2019-05-31
JP2017217003A (ja) 2017-12-14
US10781252B2 (en) 2020-09-22
CA2597098A1 (en) 2006-08-17
US9090685B2 (en) 2015-07-28
US20210061897A1 (en) 2021-03-04
JP5174466B2 (ja) 2013-04-03
BRPI0607639A2 (pt) 2009-09-22
IL184995A0 (en) 2007-12-03
US8383780B2 (en) 2013-02-26
TR201901929T4 (tr) 2019-03-21
PT3520815T (pt) 2022-02-02
MX2007009545A (es) 2008-03-11
WO2006086469A3 (en) 2007-04-19
EP1850873A2 (en) 2007-11-07
IL255078B (en) 2021-01-31
JP2016128512A (ja) 2016-07-14
JP2013031444A (ja) 2013-02-14
JP6463807B2 (ja) 2019-02-06
AU2006213875B2 (en) 2010-08-19
JP2015003917A (ja) 2015-01-08
US20140127230A1 (en) 2014-05-08
US20150284456A1 (en) 2015-10-08
JP6005703B2 (ja) 2016-10-12
CA2597098C (en) 2016-08-02
IL225752A (en) 2017-10-31
CN104177497A (zh) 2014-12-03
US20170066821A1 (en) 2017-03-09
US7723486B2 (en) 2010-05-25
CN101163502A (zh) 2008-04-16
WO2006086469A2 (en) 2006-08-17
JP5726140B2 (ja) 2015-05-27
US20110008364A1 (en) 2011-01-13
PL3520815T3 (pl) 2022-04-11
HK1201860A1 (en) 2015-09-11
CN104177497B (zh) 2018-01-16
LT1850873T (lt) 2019-04-10
BRPI0607639B1 (pt) 2022-04-05
PL1850873T3 (pl) 2019-06-28
US8591901B2 (en) 2013-11-26
JP6341945B2 (ja) 2018-06-13
IL184995A (en) 2013-04-30
US20230078449A1 (en) 2023-03-16
US20060251658A1 (en) 2006-11-09
CY1121424T1 (el) 2020-05-29
US10174108B2 (en) 2019-01-08
DK1850873T3 (en) 2019-03-18
US20070134246A1 (en) 2007-06-14
HK1201859A1 (en) 2015-09-11
US9481726B2 (en) 2016-11-01
JP2008529503A (ja) 2008-08-07
US20070264255A1 (en) 2007-11-15
EP1850873B1 (en) 2018-11-28
HUE042689T2 (hu) 2019-07-29
AU2006213875A1 (en) 2006-08-17
ES2905923T3 (es) 2022-04-12
IL255078A0 (en) 2017-12-31
ES2711213T3 (es) 2019-04-30
EP3520815A1 (en) 2019-08-07
EP1850873A4 (en) 2012-06-13
EP3520815B1 (en) 2021-11-17
US20190177406A1 (en) 2019-06-13
US20130243788A1 (en) 2013-09-19
IL225752A0 (en) 2013-06-27
CA2930677A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
EP1850873A4 (en) ANTIBODIES AGAINST TGFBETA
HK1218126A1 (zh) 抗體
IL189599A0 (en) Methods to enhance chemotherapy
IL191340A (en) Monoclonal antibodies against e8o
ZA200709291B (en) Antibodies to myostatin
ZA200900395B (en) Antibodies directed to +-Vß6 and uses thereof
IL187106A (en) Sclerostin binds antibody
IL190472A0 (en) Anti-glypican-3 antibody
GB0503546D0 (en) Antibody
PT2011869E (pt) Novo anticorpo anti-cd98
GB0517487D0 (en) Antibodies
EP1869192A4 (en) FRAME MIXTURE OF ANTIBODIES
EP2125890A4 (en) ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4
EP2212431A4 (en) ANTI-IREM-1 ANTIBODIES
IL172276A0 (en) Cross-reference to related application
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES
GB0505489D0 (en) Antibodies
ZA200804254B (en) Human monoclonal antibodies to O8E
GB0512278D0 (en) Antibodies
GB0505054D0 (en) Antibodies
GB0517718D0 (en) Further improvement to brikmat
GB2423802B (en) Improvements relating to vacuum-brake-boosters
GB0500847D0 (en) Claims to be made
GB0519883D0 (en) Antibodies
GB0413163D0 (en) Improvements to signware